These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 7153071

  • 1. [Therapeutic considerations in vascular diseases of the inner ear].
    Hesch RD.
    HNO; 1982 Oct; 30(10):365-74. PubMed ID: 7153071
    [Abstract] [Full Text] [Related]

  • 2. [Evaluation of risk factors in various forms of inner ear hearing loss].
    Hesse G, Hesch RD.
    HNO; 1986 Dec; 34(12):503-7. PubMed ID: 3818370
    [Abstract] [Full Text] [Related]

  • 3. [Acute diseases of the inner ear--are cardiovascular treatment strategies lacking?].
    Suckfüll M.
    MMW Fortschr Med; 2004 Apr 08; 146(15):52-5. PubMed ID: 15373021
    [Abstract] [Full Text] [Related]

  • 4. Is there a role for atrial peptides in the labyrinthine "disease"?
    Borghi C, Modugno GC, Brandolini C, Pirodda A.
    Med Hypotheses; 2006 Apr 08; 66(6):1188-90. PubMed ID: 16431035
    [Abstract] [Full Text] [Related]

  • 5. [Pharmacologic aspects in the management of inner ear disease (author's transl)].
    Breuninger H.
    HNO; 1976 Oct 08; 24(10):329-32. PubMed ID: 11201
    [Abstract] [Full Text] [Related]

  • 6. Treatment of vascular inner ear disease in vascular patients with pentoxifylline: a controlled, randomized trial.
    Cesarone MR, Incandela L, Belcaro G, De Sanctis MT, Nicolaides AN, Griffin M, Geroulakos G, Ramaswami G.
    Angiology; 2002 Oct 08; 53 Suppl 1():S23-6. PubMed ID: 11865831
    [Abstract] [Full Text] [Related]

  • 7. Treatment of vascular inner ear disease with pentoxifylline: a 4-week, controlled, randomized trial.
    Incandela L, Cesarone MR, Belcaro G, De Sanctis MT, Nicolaides AN, Griffin M, Geroulakos G, Ramaswami G.
    Angiology; 2002 Oct 08; 53 Suppl 1():S19-22. PubMed ID: 11865830
    [Abstract] [Full Text] [Related]

  • 8. [Activity of ginkgo-biloba in ear diseases due to arteriosclerosis].
    De Amicis E.
    Minerva Med; 1973 Nov 07; 64(79 Suppl):4193-4. PubMed ID: 4592296
    [No Abstract] [Full Text] [Related]

  • 9. Inner ear dysfunction of uncertain origin: a multidisciplinary approach could give something more.
    Pirodda A, Brandolini C, Ferri GG, Modugno GC, Esposti DD, Borghi C.
    Med Hypotheses; 2009 Feb 07; 72(2):188-9. PubMed ID: 19027243
    [Abstract] [Full Text] [Related]

  • 10. Vascular diseases of the ear.
    Berberich J.
    Proc Rudolf Virchow Med Soc City N Y; 1964 Feb 07; 23():195-201. PubMed ID: 5220435
    [No Abstract] [Full Text] [Related]

  • 11. A totally implantable drug delivery system for local therapy of the middle and inner ear.
    Lehner R, Brugger H, Maassen MM, Zenner HP.
    Ear Nose Throat J; 1997 Aug 07; 76(8):567-70. PubMed ID: 9282464
    [Abstract] [Full Text] [Related]

  • 12. Type II collagen-induced autoimmune ear disease in mice: a preliminary report on an epitope of the type II collagen molecule that induced inner ear lesions.
    Takeda T, Sudo N, Kitano H, Yoo TJ.
    Am J Otol; 1996 Jan 07; 17(1):69-75. PubMed ID: 8694137
    [Abstract] [Full Text] [Related]

  • 13. [Immune-mediated inner ear disease: report of clinical cases].
    García Berrocal JR, Arellano B, Vargas JA, Trinidad A, Ramírez Camacho R, Vergara J.
    Acta Otorrinolaringol Esp; 1997 Oct 07; 48(7):565-70. PubMed ID: 9489160
    [Abstract] [Full Text] [Related]

  • 14. Brain and inner-ear fluid homeostasis, cochleovestibular-type tinnitus, and secondary endolymphatic hydrops.
    Shulman A, Goldstein B.
    Int Tinnitus J; 2006 Oct 07; 12(1):75-81. PubMed ID: 17147045
    [Abstract] [Full Text] [Related]

  • 15. Pharmacologic treatment of inner ear: from basic science to the patient.
    Lefebvre PP, Staecker H, Van de Water T, Moonen G, Malgrange B.
    Acta Otorhinolaryngol Belg; 2002 Oct 07; 56(1):45-9. PubMed ID: 11894630
    [Abstract] [Full Text] [Related]

  • 16. [Cholesterolemia control in Spain, 2000. A tool for cardiovascular disease prevention. Ministry of Health and Consumption, Spanish Society of Cardiology and Spanish Society of Arteriosclerosis].
    Rev Esp Salud Publica; 2000 Oct 07; 74(3):215-53. PubMed ID: 10918811
    [Abstract] [Full Text] [Related]

  • 17. Effect of metabolic syndrome or type II diabetes mellitus on the occurrence of recurrent vascular events in hypertensive patients.
    Vlek AL, van der Graaf Y, Spiering W, Visseren FL, SMART study group.
    J Hum Hypertens; 2008 May 07; 22(5):358-65. PubMed ID: 18273039
    [Abstract] [Full Text] [Related]

  • 18. Self-efficacy in patients with clinical manifestations of vascular diseases.
    Sol BG, van der Graaf Y, van der Bijl JJ, Goessens NB, Visseren FL.
    Patient Educ Couns; 2006 Jun 07; 61(3):443-8. PubMed ID: 16009526
    [Abstract] [Full Text] [Related]

  • 19. Angiogenesis: possible analogies between the eye and the inner ear.
    Campos EC, Gattegna R, Raimondi MC, Pirodda A.
    Med Hypotheses; 2012 May 07; 78(5):644-5. PubMed ID: 22348992
    [Abstract] [Full Text] [Related]

  • 20. [Is it possible to modify labyrinthine circulation?].
    Martin H, Martin C, Oudot J.
    J Fr Otorhinolaryngol Audiophonol Chir Maxillofac; 1978 May 07; 27(5):331-9. PubMed ID: 149834
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.